Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Prepaid Assets (2019 - 2026)

C4 Therapeutics has reported Prepaid Assets over the past 8 years, most recently at $6.8 million for Q1 2026.

  • For Q1 2026, Prepaid Assets fell 27.63% year-over-year to $6.8 million; the TTM value through Mar 2026 reached $6.8 million, down 27.63%, while the annual FY2025 figure was $7.2 million, 26.52% down from the prior year.
  • Prepaid Assets for Q1 2026 was $6.8 million at C4 Therapeutics, down from $7.2 million in the prior quarter.
  • Over five years, Prepaid Assets peaked at $10.8 million in Q2 2024 and troughed at $5.7 million in Q4 2023.
  • A 5-year average of $8.3 million and a median of $8.0 million in 2025 define the central range for Prepaid Assets.
  • Biggest five-year swings in Prepaid Assets: skyrocketed 105.07% in 2022 and later tumbled 42.51% in 2023.
  • Year by year, Prepaid Assets stood at $9.9 million in 2022, then tumbled by 42.51% to $5.7 million in 2023, then skyrocketed by 70.98% to $9.8 million in 2024, then dropped by 26.52% to $7.2 million in 2025, then dropped by 4.95% to $6.8 million in 2026.
  • Business Quant data shows Prepaid Assets for CCCC at $6.8 million in Q1 2026, $7.2 million in Q4 2025, and $8.4 million in Q3 2025.